Wall Street analysts expect that HCP, Inc. (NYSE:HCP) will report $458.84 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for HCP’s earnings. The lowest sales estimate is $442.20 million and the highest is $470.40 million. HCP posted sales of $492.17 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 6.8%. The firm is scheduled to announce its next quarterly earnings results before the market opens on Thursday, May 3rd.
According to Zacks, analysts expect that HCP will report full year sales of $1.80 billion for the current year, with estimates ranging from $1.74 billion to $1.83 billion. For the next fiscal year, analysts expect that the company will report sales of $1.81 billion per share, with estimates ranging from $1.74 billion to $1.88 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for HCP.
HCP (NYSE:HCP) last issued its earnings results on Tuesday, February 13th. The real estate investment trust reported $0.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.47 by $0.01. The firm had revenue of $443.30 million for the quarter, compared to the consensus estimate of $448.54 million. HCP had a return on equity of 6.99% and a net margin of 22.37%. The company’s revenue was down 17.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.59 EPS.
Several research firms recently weighed in on HCP. Zacks Investment Research raised HCP from a “sell” rating to a “hold” rating in a report on Monday, March 26th. Wells Fargo cut their price objective on HCP from $31.00 to $27.00 and set a “market perform” rating on the stock in a report on Tuesday, March 20th. Bank of America raised HCP from a “neutral” rating to a “buy” rating and raised their price objective for the company from $22.63 to $25.00 in a report on Thursday, March 8th. Royal Bank of Canada reissued a “hold” rating and set a $27.00 price objective on shares of HCP in a report on Friday, February 23rd. Finally, UBS reissued a “sell” rating and set a $21.00 price objective (down previously from $25.00) on shares of HCP in a report on Wednesday, February 21st. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $27.50.
Shares of HCP stock traded up $0.18 during trading hours on Thursday, reaching $22.42. The company’s stock had a trading volume of 1,937,007 shares, compared to its average volume of 4,093,043. The company has a market cap of $10,440.42, a PE ratio of 11.50, a P/E/G ratio of 5.48 and a beta of 0.26. HCP has a fifty-two week low of $21.48 and a fifty-two week high of $33.67. The company has a debt-to-equity ratio of 1.23, a quick ratio of 0.31 and a current ratio of 0.31.
In related news, insider Kendall K. Young bought 14,000 shares of the stock in a transaction that occurred on Wednesday, February 14th. The stock was acquired at an average cost of $21.91 per share, with a total value of $306,740.00. Following the transaction, the insider now directly owns 48,544 shares in the company, valued at $1,063,599.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.14% of the stock is owned by company insiders.
A number of large investors have recently made changes to their positions in the stock. BerganKDV Wealth Management LLC raised its position in HCP by 4.2% during the 4th quarter. BerganKDV Wealth Management LLC now owns 51,797 shares of the real estate investment trust’s stock worth $1,351,000 after purchasing an additional 2,110 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its position in HCP by 3.5% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 76,216 shares of the real estate investment trust’s stock worth $2,113,000 after purchasing an additional 2,601 shares during the last quarter. Norinchukin Bank The raised its position in HCP by 7.5% during the 4th quarter. Norinchukin Bank The now owns 37,508 shares of the real estate investment trust’s stock worth $978,000 after purchasing an additional 2,601 shares during the last quarter. Exane Derivatives raised its position in HCP by 5.2% during the 4th quarter. Exane Derivatives now owns 52,863 shares of the real estate investment trust’s stock worth $1,379,000 after purchasing an additional 2,628 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado raised its position in HCP by 3.5% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 88,232 shares of the real estate investment trust’s stock worth $2,301,000 after purchasing an additional 2,992 shares during the last quarter. 88.49% of the stock is owned by institutional investors and hedge funds.
HCP Company Profile
HCP, Inc is a self-administered real estate investment trust. The Company invests in real estate serving the healthcare industry in the United States. The Company’s segments include senior housing triple-net (SH NNN), senior housing operating portfolio (SHOP), life science and medical office. Its senior housing facilities include independent living facilities, assisted living facilities, memory care facilities, care homes, and continuing care retirement communities.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.